At the 2025 Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, investigators presented the first data readout from the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) registry, showing the utility of real-world evidence to understand Alzheimer’s disease treatment in routine clinical practice. ALZ-NET is a nationwide, clinician-enrolled patient registry, established by the American Alzheimer’s Association, that collects standardised real-world clinical and imaging data from people being evaluated for memory concerns or treated with FDA-approved Alzheimer’s therapies across more than 118 active clinical sites and over 3,600 enrolled individuals in the United States.
The data presented at CTAD showed that demographic characteristics of participants in ALZ-NET mirror those seen in clinical trial populations, and that most individuals receiving anti-amyloid targeting therapies were in early clinical stages of Alzheimer’s disease. For a subset of more than 600 participants treated with anti-amyloid therapies, initial observations indicated that cognitive and functional measures remained stable during the first year of treatment, and safety outcomes, including rates of amyloid-related imaging abnormalities (ARIA), aligned with expectations based on controlled trials. No ARIA-related deaths were reported in the registry cohort.
The ALZ-NET presentations also cited the potential of real-world data to reinforce findings from traditional clinical trials and support broader clinical decision-making. Presenters highlighted the importance of continued participation by clinicians, health systems and patients to strengthen the evidence base, as well as the new capability for researchers and clinicians to request access to ALZ-NET datasets through an independent Data Access and Use Committee, facilitating further research into how Alzheimer’s treatments are used and how patients respond in real-life settings. Learn more about ALZ-NET: https://www.alz-net.org/about-alz-net/about-us
